NJ-DRIVEWEALTH
13.7.2022 15:02:09 CEST | Business Wire | Press release
DriveWealth, LLC , a global fintech investment rail and pioneer in fractional investing, today released its new DriveTrends study, “The Year of The Millennial Trader: Trading Remained Trendy Despite Market Uncertainty ,” a closer look at how the first prolonged bear market many investors have faced impacted trading behaviors of millions across APAC, EMEA, LATAM, and the U.S. during the first half of 2022. The study analyzes data of more than 12 million investors worldwide who trade shares of U.S. equities through DriveWealth’s network of 100+ global partners, including Block Inc.’s Cash App, Revolut, and Navy Federal Financial Group.
Even amid market lows, data shows trading remained popular among Millennials, a demographic that continues to demand more access to traditional and alternative investment products and tools. The report showcases how Millennials’ increasing preference for innovations like fractional equity trades and diversified portfolios have shaped a new market for digital wallet app users , which is anticipated to exceed 4.4 billion by 2025, according to Juniper Research .
“The ability for providers to offer fractionalized trading has provided a whole new segment of consumers with the opportunity to access wealth creating markets using the smartphones they already own,” said Harry Temkin , Chief Information Officer at DriveWealth. “Millennials are motivating fintechs and neobanks to innovate their product suite to improve access to U.S. equities and financial literacy tools in underserved markets. Our recent partnerships with companies like Toss Securities , Goalsetter , and Sproutfi are testaments to the amount of power Millennials have to shape the financial ecosystem at large – all they need is an investment button that’s now accessible in the palm of their hand.”
Based on data from the first half of 20221 , key takeaways from the report include:
- Millennials represented the largest proportion of new investment account openings worldwide at 46%. While data showed that almost half of Gen-Z investors opened their first account during the March 2020 to August 2021 period (representing a large and growing market share of investors), Gen-Z scaled back while Millennials took the lead this year. This could signal a potential influx of cash into investment platforms that meet their investing needs, as U.S. Millennial wealth has more than doubled from the fourth quarter of 2019 to the end of 2021.
- While ‘meme stocks’ and Reddit comments continued to inspire news headlines, the report shows global investors (especially younger ones) gravitated toward more tried-and-true names to create their portfolios. AAPL, TSLA, and AMZN continue to retain their position as the top three symbols traded worldwide.
-
Millennials represented both the highest average trades per account (19) worldwide and the largest proportion of trades in each region. This generation drove:
- 94% of trades in APAC
- 69% of trades in EMEA
- 53% of trades in LATAM
- 53% of trades in the U.S.
- Across the U.S., LATAM, and EMEA, approximately 96% of all activity was driven by fractionalized trades through DriveWealth’s platform. This is a measurable increase from the second half of 2020, where fractional trades drove 92% of global activity.
- The top two traded symbols among Millennials in APAC were TQQQ and SQQQ, triple-leveraged ETFs that track a Nasdaq 100 index ETF, QQQ. Known as a high-risk sector, this suggests Millennials in this region may be motivated by riskier investments with the potential for high returns.
“As we dive deeper into the Decade of the Digital Investor , we’re seeing a paradigm shift in investing,” said Gayathri Rajan , Chief Product Officer at DriveWealth. “Despite market uncertainty, people – especially younger investors – are still investing in the brands they love using digital tools that are making markets accessible and affordable for them. As a pioneer of fractional trading, we’re excited to continue working with our partners to develop even more ways for investors worldwide to access the markets through our API-based platform.”
To read the full results of “The Year of The Millennial Trader: Trading Remained Trendy Despite Market Uncertainty,” click here . For more information on DriveWealth’s full suite of services, see here .
About DriveWealth
DriveWealth , a global fintech investment rail and pioneer of fractional equities trading, is a visionary technology company that empowers more than 100 partners around the world to engage their customers by placing the markets in the palm of their hands. We believe the future is fractional, transactional and mobile. Every mobile device should be a gateway to accessing investing and savings products, services, advice, and assistance for global citizens of all ages, wealth stages, and levels of financial expertise. DriveWealth’s consultative support and cloud-based, modern technology platform allow partners to seamlessly offer branded investing experiences to drive customer acquisition, loyalty, retention, and revenue growth. For more information, please visit drivewealth.com or connect with us on Twitter @DriveWealth or on LinkedIn .
1 DriveWealth proprietary data. All data has been rounded and reflects approximate figures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005508/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom